Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio ...
A cell’s morphology comprises vast amounts of information on cell health and differentiation state and yields insight into cell phenotype. Biologists utilize this information on a daily basis to aid ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
The overall process for developing and manufacturing vaccines and cell and gene therapies (CGTs) is challenging and resource intensive because it involves complex and variable raw materials, demanding ...
A team of researchers at IOCB Prague headed by Dr. Tomáš Slanina has developed a new method for labeling molecules with ...
Proliferation assays provide quantitative evaluation of a cell population’s viability and growth, and are a crucial aspect of cancer biology research. There are various types of proliferation assays, ...
As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...
Clinical Trials Arena on MSN
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints
"Capricor stock soars after pivotal DMD cell therapy trial meets endpoints" was originally created and published by Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback